Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.
- Published In:
- The lancet. Diabetes & endocrinology, 13(11), 949-963 (2025)
- Authors:
- Wharton, Sean(7), Freitas, Paula, Hjelmesæth, Jøran, Kabisch, Maria, Kandler, Kristian, Lingvay, Ildiko, Quiroga, Maria, Rosenstock, Julio, Garvey, W Timothy
- Database ID:
- RPEP-14140
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14140APA
Wharton, Sean; Freitas, Paula; Hjelmesæth, Jøran; Kabisch, Maria; Kandler, Kristian; Lingvay, Ildiko; Quiroga, Maria; Rosenstock, Julio; Garvey, W Timothy. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.. The lancet. Diabetes & endocrinology, 13(11), 949-963. https://doi.org/10.1016/S2213-8587(25)00226-8
MLA
Wharton, Sean, et al. "Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.." The lancet. Diabetes & endocrinology, 2025. https://doi.org/10.1016/S2213-8587(25)00226-8
RethinkPeptides
RethinkPeptides Research Database. "Once-weekly semaglutide 7·2 mg in adults with obesity (STEP ..." RPEP-14140. Retrieved from https://rethinkpeptides.com/research/wharton-2025-onceweekly-semaglutide-72-mg
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.